TCR2 Therapeutics Inc.
TCRRDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750019
TCR2 Therapeutics Inc. was delisted in 2023; its insiders filed their last Form 4 on Feb 14, 2024; 59 institutions reported holding it in 13F filings for Q1 2023, worth $31.7M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 59
- Q1 2023, −4 vs. previous quarter
- 13F value
- $31.5M
- Reported value at the end of Q1 2023
- Superinvestors holding
- 0
- At the end of Q1 2023
Superinvestors holding TCRR, Q1 2023
No superinvestor reported holding TCRR at the end of Q1 2023.
Latest insider trades
Open-market purchases and sales by TCR2 Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 30, 2023 (view filing)8:02 PM ET | May 25 | 5 days | Tang Kevin C and 2 others10% Owner | PPurchase | +50.0K | $1.72 | +$86.0K | +1.2%4.39M after | |
| May 24, 2023 (view filing)4:39 PM ET | May 22 | 2 days | Evnin Luke and 1 other10% Owner | SSale | −70.2K | $1.88 | −$131.9K | −18.8%304.0K after | Duplicate filing |
| May 24, 2023 (view filing) | May 22 | 2 days | Gadicke AnsbertDirector, 10% Owner | SSale | −70.2K | $1.88 | −$131.9K | −18.8%304.0K after | |
| May 15, 2023 (view filing)5:12 PM ET | May 11-12 | 4 days | Tang Kevin C and 2 others10% Owner | PPurchase | +44.9K | $1.95 | +$87.6K | +1.0%4.34M after | 2 lots |
| May 10, 2023 (view filing)7:02 PM ET | May 8-10 | 2 days | Tang Kevin C and 2 others10% Owner | PPurchase | +84.0K | $1.95 | +$163.8K | +2.0%4.30M after | 3 lots |
| May 5, 2023 (view filing)6:52 PM ET | May 3-5 | 2 days | Tang Kevin C and 2 others10% Owner | PPurchase | +289.6K | $1.89 | +$547.9K | +7.4%4.22M after | 4 lots |
| Dec 13, 2022 (view filing) | Dec 9-13 | 4 days | Cardama Alfonso QuintasChief Medical Officer | SSale | −13.8K | $1.10 | −$15.1K | −11.2%109.5K after | 3 lots |
| Dec 13, 2022 (view filing) | Dec 9-13 | 4 days | Olagunju PeterChief Technical Officer | SSale | −4.83K | $1.10 | −$5.31K | −16.7%24.1K after | 3 lots |
| Dec 13, 2022 (view filing) | Dec 9-12 | 4 days | Justice AngelaChief People Officer | SSale | −8.62K | $1.10 | −$9.45K | −15.0%48.7K after | 3 lots |
| Dec 13, 2022 (view filing) | Dec 9-13 | 4 days | Menzel Garry EPresident and CEO | SSale | −31.9K | $1.10 | −$35.0K | −18.7%138.9K after | 3 lots |
Top 10 13F holders, Q1 2023
The largest institutional positions in TCR2 Therapeutics Inc. at the end of Q1 2023; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| MPM Asset Management LLC | 4,050,865 | $6.08M | 2.53% | 00.0% | Unchanged |
| Tang Capital Management LLC | 3,399,745 | $5.10M | 0.76% | +660,798+24.1% | Added |
| MPM Oncology Impact Management LP | 3,370,982 | $5.06M | 1.31% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,468,802 | $2.20M | 0.00% | +37,456+2.6% | Added |
| Newtyn Management, LLC | 1,015,920 | $1.52M | 0.30% | −59,080−5.5% | Reduced |
| Acadian Asset Management LLC | 812,459 | $1.22M | 0.01% | −62,394−7.1% | Reduced |
| BlackRock Inc. | 789,911 | $1.18M | 0.00% | −962−0.1% | Reduced |
| Baker Bros. Advisors LP | 753,064 | $1.13M | 0.01% | 00.0% | Unchanged |
| Artal Group S.A. | 750,000 | $1.13M | 0.07% | 00.0% | Unchanged |
| Redmile Group, LLC | 658,336 | $987.5K | 0.04% | −73,043−10.0% | Reduced |